How Biocare Helps GLP-1 Nausea*
GLP-1 medications are known to delay gastric emptying as part of their mechanism of action. This slower movement of food from the stomach to the small intestine helps control blood sugar levels and promotes satiety. However, it can also lead to side effects like nausea.
The bioactive ingredients in Biocare that help support stomach calming include Glycyrrhiza glabra (Licorice) Root Extract and Zinc L-Carnosine, both of which ease digestive irritations that can result in nausea. Additionally, in some cases, the digestive enzyme blend may also help if the nausea is caused by undigested food in the stomach.*
Biocare’s proprietary formula contains bioactive anti-nausea compounds & digestive enzymes to help reduce nausea caused by GLP-1 medications
High-Protein, Friendly Nutrition
Discover your favorite flavor with the Biocare 30G Protein Beverage Variety Pack! This 7-count pack includes a delicious mix of beverages — 2 Vanilla, 2 Chocolate, 2 Chocolate Salted Caramel, and 1 Strawberries & Cream — each packed with 30 grams of high-quality protein, essential vitamins, and anti-nausea ingredients. Specially designed for individuals on a GLP journey, these beverages help combat side effects while supporting weight management, muscle maintenance and overall wellness. Perfect for variety, convenience, and great taste — try Biocare’s protein beverage variety pack today!
• Wilding, John P.H., et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 10 Feb. 2021, www.nejm.org/doi/full/10.1056/NEJMoa2032183
• Garvey, W. Timothy, et al. “Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: The Step 5 Trial.” Nature News, Nature Publishing Group, 10 Oct. 2022, www.nature.com/articles/s41591-022-02026-4
+ Wilding, John P.H., et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 10 Feb. 2021, www.nejm.org/doi/full/10.1056/NEJMoa2032183
++ Garvey, W. Timothy, et al. “Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: The Step 5 Trial.” Nature News, Nature Publishing Group, 10 Oct. 2022, www.nature.com/articles/s41591-022-02026-4
